TUBGCP2

Across TCGA pan-cancer cohorts, TUBGCP2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TUBGCP2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TUBGCP2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TUBGCP2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where TUBGCP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TUBGCP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	All	+0.202	<.001	11	view →
LSCC	Female	All	−0.180	<.001	8	view →
LUAD	Female	All	−0.167	<.001	7	view →
CCRCC	All	All	+0.059	.002	6	view →
PDAC	Male	III,IV	+0.303	.022	4	view →
COAD	Male	III,IV	−0.133	.020	4	view →
OV	All	All	−0.192	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TUBGCP2–HNSC

Open the HNSC breakdown →